Tech Company Financing Transactions
Epiphany Biosciences Funding Round
On 3/15/2007, Epiphany Biosciences raised $36 million in Series A funding from Wexford Capital and CDIB Bioscience.
Transaction Overview
Company Name
Announced On
3/15/2007
Transaction Type
Venture Equity
Amount
$36,000,000
Round
Series A
Investors
Wexford Capital (Lead Investor)
Proceeds Purpose
"The funding will enable us to advance our lead programs including our anti-viral drug candidate Valomaciclovir (EPB-348) through Phase 2b clinical trials against shingles as well as Epiphany's development of HHV-8/KSHV screening diagnostics," added David Myles, PhD, COO.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 California St. 2800
San Francisco, CA 94111
USA
San Francisco, CA 94111
USA
Phone
Website
Email Address
Overview
Epiphany Biosciences is a biotechnology company focused on developing new therapeutics and diagnostic technologies that treat or prevent the spread of diseases of viral origin.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Fred Volinsky
Chief Medical Officer
Howard Worman
Browse more venture capital transactions:
Prev: 3/15/2007: MovingHealth venture capital transaction
Next: 3/16/2007: Socializr venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs